Repligen Corporation (RGEN) - Net Assets
Based on the latest financial reports, Repligen Corporation (RGEN) has net assets worth $2.11 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.95 Billion) and total liabilities ($838.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Repligen Corporation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.11 Billion |
| % of Total Assets | 71.59% |
| Annual Growth Rate | 14.78% |
| 5-Year Change | 20.35% |
| 10-Year Change | 1147.97% |
| Growth Volatility | 137.19 |
Repligen Corporation - Net Assets Trend (1985–2025)
This chart illustrates how Repligen Corporation's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Repligen Corporation stock valuation.
Annual Net Assets for Repligen Corporation (1985–2025)
The table below shows the annual net assets of Repligen Corporation from 1985 to 2025. Also explore Repligen Corporation equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.11 Billion | +6.76% |
| 2024-12-31 | $1.97 Billion | +0.08% |
| 2023-12-31 | $1.97 Billion | +3.17% |
| 2022-12-31 | $1.91 Billion | +9.18% |
| 2021-12-31 | $1.75 Billion | +14.45% |
| 2020-12-31 | $1.53 Billion | +44.29% |
| 2019-12-31 | $1.06 Billion | +5506.15% |
| 2018-12-31 | $-19.60 Million | +37.78% |
| 2017-12-31 | $-31.51 Million | -118.67% |
| 2016-12-31 | $168.76 Million | +37.49% |
| 2015-12-31 | $122.75 Million | +249.72% |
| 2014-12-31 | $-81.99 Million | -178.92% |
| 2013-12-31 | $103.89 Million | +23.49% |
| 2012-12-31 | $84.12 Million | +27.46% |
| 2011-12-31 | $66.00 Million | -1.62% |
| 2010-12-31 | $67.09 Million | +1.32% |
| 2009-12-31 | $66.21 Million | -3.28% |
| 2008-12-31 | $68.46 Million | +6.61% |
| 2007-12-31 | $64.21 Million | +163.77% |
| 2006-12-31 | $24.34 Million | -2.87% |
| 2005-12-31 | $25.06 Million | +2.54% |
| 2004-12-31 | $24.44 Million | -7.06% |
| 2003-12-31 | $26.30 Million | -13.33% |
| 2002-12-31 | $30.34 Million | +12.93% |
| 2001-12-31 | $26.87 Million | -8.86% |
| 2000-12-31 | $29.48 Million | -15.84% |
| 1999-12-31 | $35.03 Million | +775.13% |
| 1998-12-31 | $4.00 Million | -24.47% |
| 1997-12-31 | $5.30 Million | -17.19% |
| 1996-12-31 | $6.40 Million | +30.61% |
| 1995-12-31 | $4.90 Million | -68.59% |
| 1994-12-31 | $15.60 Million | -45.07% |
| 1993-12-31 | $28.40 Million | -19.32% |
| 1992-12-31 | $35.20 Million | -31.78% |
| 1991-12-31 | $51.60 Million | +0.39% |
| 1990-12-31 | $51.40 Million | +46.02% |
| 1989-12-31 | $35.20 Million | +65.26% |
| 1988-12-31 | $21.30 Million | -13.77% |
| 1987-12-31 | $24.70 Million | +20.49% |
| 1986-12-31 | $20.50 Million | +141.18% |
| 1985-12-31 | $8.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Repligen Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 45984800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $456.25 Million | 21.66% |
| Common Stock | $563.00K | 0.03% |
| Other Comprehensive Income | $-2.53 Million | -0.12% |
| Other Components | $1.65 Billion | 78.43% |
| Total Equity | $2.11 Billion | 100.00% |
Repligen Corporation Competitors by Market Cap
The table below lists competitors of Repligen Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bentley Systems Inc
NASDAQ:BSY
|
$9.32 Billion |
|
Chart Industries Inc
NYSE:GTLS
|
$9.32 Billion |
|
Masimo Corporation
NASDAQ:MASI
|
$9.34 Billion |
|
FirstCash Inc
NASDAQ:FCFS
|
$9.35 Billion |
|
Kymera Therapeutics Inc
NASDAQ:KYMR
|
$9.31 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
$9.31 Billion |
|
Hotai Motor Co Ltd
TW:2207
|
$9.30 Billion |
|
Chandra Asri Petrochemical Tbk
JK:TPIA
|
$9.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Repligen Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,972,718,000 to 2,106,129,000, a change of 133,411,000 (6.8%).
- Net income of 48,894,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 50,002,000.
- Other factors increased equity by 34,515,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $48.89 Million | +2.32% |
| Other Comprehensive Income | $50.00 Million | +2.37% |
| Other Changes | $34.52 Million | +1.64% |
| Total Change | $- | 6.76% |
Book Value vs Market Value Analysis
This analysis compares Repligen Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 24.70x to 4.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $7.07 | $174.73 | x |
| 1986-12-31 | $4.34 | $174.73 | x |
| 1987-12-31 | $3.00 | $174.73 | x |
| 1988-12-31 | $3.90 | $174.73 | x |
| 1989-12-31 | $4.55 | $174.73 | x |
| 1990-12-31 | $5.68 | $174.73 | x |
| 1991-12-31 | $4.60 | $174.73 | x |
| 1992-12-31 | $2.90 | $174.73 | x |
| 1993-12-31 | $2.23 | $174.73 | x |
| 1994-12-31 | $1.02 | $174.73 | x |
| 1995-12-31 | $0.32 | $174.73 | x |
| 1996-12-31 | $0.38 | $174.73 | x |
| 1997-12-31 | $0.32 | $174.73 | x |
| 1998-12-31 | $1.95 | $174.73 | x |
| 1999-12-31 | $1.43 | $174.73 | x |
| 2000-12-31 | $1.00 | $174.73 | x |
| 2001-12-31 | $0.92 | $174.73 | x |
| 2002-12-31 | $1.13 | $174.73 | x |
| 2003-12-31 | $0.82 | $174.73 | x |
| 2004-12-31 | $0.85 | $174.73 | x |
| 2005-12-31 | $0.83 | $174.73 | x |
| 2006-12-31 | $2.11 | $174.73 | x |
| 2007-12-31 | $2.21 | $174.73 | x |
| 2008-12-31 | $2.11 | $174.73 | x |
| 2009-12-31 | $2.18 | $174.73 | x |
| 2010-12-31 | $2.18 | $174.73 | x |
| 2011-12-31 | $2.14 | $174.73 | x |
| 2012-12-31 | $2.69 | $174.73 | x |
| 2013-12-31 | $3.21 | $174.73 | x |
| 2014-12-31 | $3.36 | $174.73 | x |
| 2015-12-31 | $3.66 | $174.73 | x |
| 2016-12-31 | $4.95 | $174.73 | x |
| 2017-12-31 | $-0.80 | $174.73 | x |
| 2018-12-31 | $13.54 | $174.73 | x |
| 2019-12-31 | $21.54 | $174.73 | x |
| 2020-12-31 | $28.37 | $174.73 | x |
| 2021-12-31 | $30.56 | $174.73 | x |
| 2022-12-31 | $33.26 | $174.73 | x |
| 2023-12-31 | $34.96 | $174.73 | x |
| 2024-12-31 | $35.27 | $174.73 | x |
| 2025-12-31 | $37.24 | $174.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Repligen Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.62%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.40x
- Recent ROE (2.32%) is above the historical average (-76.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | -6.60% | -38.89% | 0.35x | 0.49x | $-3.52 Million |
| 1986 | -82.80% | -559.46% | 0.16x | 0.92x | $-23.20 Million |
| 1987 | 1.37% | 2.94% | 0.37x | 1.26x | $-1.89 Million |
| 1988 | -11.79% | -38.82% | 0.34x | 0.88x | $-6.10 Million |
| 1989 | -6.82% | -18.90% | 0.34x | 1.07x | $-5.92 Million |
| 1990 | -11.09% | -75.00% | 0.14x | 1.05x | $-10.84 Million |
| 1991 | -24.81% | -109.40% | 0.20x | 1.14x | $-17.96 Million |
| 1992 | -32.10% | -41.39% | 0.58x | 1.35x | $-14.82 Million |
| 1993 | -68.66% | -72.76% | 0.65x | 1.45x | $-22.34 Million |
| 1994 | -205.13% | -189.35% | 0.54x | 2.01x | $-33.56 Million |
| 1995 | -234.69% | -105.50% | 1.91x | 1.16x | $-11.99 Million |
| 1996 | -7.81% | -13.16% | 0.57x | 1.05x | $-1.14 Million |
| 1997 | -15.09% | -33.33% | 0.42x | 1.08x | $-1.33 Million |
| 1998 | -7.12% | -96.15% | 0.50x | 0.15x | $-6.01 Million |
| 1999 | -12.35% | -110.60% | 0.10x | 1.17x | $-6.91 Million |
| 2000 | -19.96% | -224.95% | 0.07x | 1.22x | $-7.92 Million |
| 2001 | -18.17% | -103.70% | 0.15x | 1.19x | $-6.92 Million |
| 2002 | -14.95% | -58.38% | 0.23x | 1.09x | $-7.57 Million |
| 2003 | -39.32% | -138.13% | 0.23x | 1.22x | $-11.98 Million |
| 2004 | -11.73% | -31.87% | 0.34x | 1.09x | $-5.53 Million |
| 2005 | 2.73% | 5.40% | 0.45x | 1.12x | $-1.86 Million |
| 2006 | -1.39% | -6.32% | 0.48x | 0.45x | $-7.30 Million |
| 2007 | 53.68% | 192.30% | 0.28x | 1.00x | $30.19 Million |
| 2008 | 8.69% | 19.57% | 0.40x | 1.12x | $-866.01K |
| 2009 | -6.06% | -19.38% | 0.29x | 1.06x | $-10.77 Million |
| 2010 | -0.06% | -0.16% | 0.38x | 1.08x | $-6.75 Million |
| 2011 | -2443.37% | -6.88% | 308.15x | 1.15x | $-1.62 Billion |
| 2012 | 16.83% | 22.73% | 0.64x | 1.15x | $5.74 Million |
| 2013 | 15.49% | 23.61% | 0.57x | 1.14x | $5.70 Million |
| 2014 | 7.31% | 12.86% | 0.00x | -0.59x | $-3.00 Million |
| 2015 | 7.61% | 11.19% | 0.57x | 1.19x | $-2.93 Million |
| 2016 | 6.92% | 11.17% | 0.36x | 1.71x | $-5.20 Million |
| 2017 | 0.00% | 20.07% | 1.17x | 0.00x | $31.50 Million |
| 2018 | 2.70% | 8.56% | 1.39x | 0.23x | $-44.94 Million |
| 2019 | 2.02% | 7.92% | 0.19x | 1.32x | $-84.57 Million |
| 2020 | 3.92% | 16.36% | 0.19x | 1.24x | $-92.99 Million |
| 2021 | 7.33% | 19.13% | 0.28x | 1.35x | $-46.72 Million |
| 2022 | 9.73% | 23.20% | 0.32x | 1.32x | $-5.11 Million |
| 2023 | 2.11% | 6.51% | 0.23x | 1.43x | $-155.54 Million |
| 2024 | -1.29% | -4.02% | 0.22x | 1.43x | $-222.79 Million |
| 2025 | 2.32% | 6.62% | 0.25x | 1.40x | $-161.72 Million |
Industry Comparison
This section compares Repligen Corporation's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,953,985,100
- Average return on equity (ROE) among peers: -136.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Repligen Corporation (RGEN) | $2.11 Billion | -6.60% | 0.40x | $9.31 Billion |
| Akoya Biosciences Inc (AKYA) | $53.77 Million | -117.77% | 2.35x | $64.44 Million |
| Align Technology Inc (ALGN) | $3.60 Billion | 10.04% | 0.65x | $10.53 Billion |
| AngioDynamics Inc (ANGO) | $37.23 Million | 8.44% | 0.34x | $648.09 Million |
| AptarGroup Inc (ATR) | $313.30 Million | 11.39% | 0.78x | $7.66 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $2.21 Billion |
| Avinger Inc (AVGR) | $4.24 Million | -1323.46% | 11.63x | $1.52 Million |
| Avantor Inc (AVTR) | $5.57 Billion | -9.53% | 1.12x | $9.19 Billion |
| Azenta Inc (AZTA) | $1.21 Billion | 5.34% | 0.28x | $1.45 Billion |
| Baxter International Inc (BAX) | $2.83 Billion | 11.40% | 1.70x | $12.26 Billion |
| Becton Dickinson and Company (BDX) | $5.43 Billion | 24.24% | 0.78x | $48.93 Billion |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, … Read more